[144] United Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

Form 144 notice for proposed sale of securities under Rule 144. The filing shows 11,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 08/21/2025 with an aggregate market value of $3,396,248.90 and the issuer reported 45,226,262 shares outstanding. The securities were acquired on 08/21/2025 by stock option exercise and payment was in cash. The filing also lists multiple recent sales by Paul Mahon totaling 66,000 shares in the past three months. The notice includes the standard signature representation that the seller has no undisclosed material adverse information.

Positive

• Detailed transaction disclosure: The filing lists the exact shares, broker, sale date, and acquisition method, supporting regulatory transparency.
• Broker identified: Sales are to be executed through Morgan Stanley Smith Barney LLC, providing a clear execution venue.
• Seller certification included: The signer represents no undisclosed material adverse information, consistent with Rule 144 requirements.

Negative

• Frequent insider sales: Seven transactions in the past three months total 66,000 shares, increasing available share supply.
• Missing issuer identification: The provided extract does not state the issuer name in the issuer information section.
• Partial filer contact data: Submission contact fields in the extract are blank, limiting traceability of the filing origin.

Insights

Securities Analyst

TL;DR: Insider executed options and repeatedly sold shares; total recent disposals equal 66,000 shares, indicating notable insider liquidity.

The filing documents a Rule 144 notice for 11,000 common shares to be sold via Morgan Stanley on 08/21/2025, acquired the same day via option exercise and paid in cash. The inclusion of seven prior sales by the same person over six weeks is material for share supply; those transactions total 66,000 shares. The filing is procedural and provides transparent transaction detail but does not disclose the issuer name in the provided tables.

Corporate Governance Expert

TL;DR: The filing meets Rule 144 disclosure requirements but omits issuer identification in the provided extract.

The notice contains the required sale and acquisition details, broker identification, and the seller's certification regarding undisclosed material information, supporting compliance with securities rules. However, the provided content lacks a clearly stated issuer name and some filer contact fields are blank, which reduces clarity for stakeholders reviewing governance and insider activity records.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	11000	3396248.90	45226262	08/21/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/21/2025	Stock Option Exercise	Issuer			11000	08/21/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	08/07/2025	11000	3299980.20
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	07/24/2025	11000	3345224.30
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	07/10/2025	11000	3303393.50
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	06/26/2025	11000	3142717.60
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	06/12/2025	11000	3079513.80
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/29/2025	4000	1263080.00
PAUL MAHON 1000 SPRING STREET SILVER SPRING MD 20910	Common	05/29/2025	7000	2213684.90

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for UTHR indicate about the proposed sale?

The form indicates 11,000 shares of common stock are proposed to be sold via Morgan Stanley on 08/21/2025 with an aggregate market value of $3,396,248.90.

How were the 11,000 shares acquired according to the filing?

The filing states the shares were acquired on 08/21/2025 through a stock option exercise and payment was made in cash.

Who has sold shares in the past three months according to this filing?

The filing lists sales by Paul Mahon totaling 66,000 shares across seven transactions dated from 05/29/2025 to 08/07/2025.

Does the filing identify the broker executing the sale?

Yes. The broker listed is Morgan Stanley Smith Barney LLC, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

Is there any undisclosed material information claimed by the seller?

By signing, the seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed.